You can buy or sell ALDR and other stocks, options, ETFs, and crypto commission-free!
Alder BioPharmaceuticals, Inc. Common Stock, also called Alder BioPharmaceuticals, is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Read More Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.
52 Week High
52 Week Low
Seeking AlphaMar 5
Alder Biopharma closes stock offering and private placement
Alder BioPharmaceuticals (NASDAQ:ALDR) closes its previously announced public offering of 13M shares of common stock, priced at $11.50/share.
Stock Price, News, & Analysis for Alder Biopharmaceuticals
News articles about ALDR stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alder Biopharmaceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave news coverage ab...
Seeking AlphaFeb 28
Alder Bio prices stock offering at $11.50; shares down 2% premarket
Alder BioPharmaceuticals (NASDAQ:ALDR) prices its public offering of ~11.3M shares of common stock at $11.50 per share. Underwriters over-allotment is an additional ~1.7M shares. Closing date is March 4. Yesterday's close was $12.21....
Expected May 7, After Hours